研究方向：缩氨基硫脲类金属化合物的抗肿瘤机制研究
在读期间发表论文：
1. Li WJ, Li SH, Zhu MH, Xu G, Man XY, Zhang ZL, Liang H*, Yang F*. Developing a rhodium(III) complex to reprogram the tumor immune and metabolic microenvironments: overcoming multidrug resistance and metastasis in non-small cell lung cancer. Journal of Medicinal Chemistry, 2024, 67, DOI: 10.1021/acs.jmedchem.4c01133
2. Li WJ, Li T, Pan Y, Li SH, Xu G, Zhang ZL, Liang H*, Yang F*. Designing a mitochondria-targeted theranostic cyclometalated iridium(Ⅲ) complex: Overcoming cisplatin resistance and inhibiting tumor metastasis through necroptosis and immune response. Journal of Medicinal Chemistry, 2024, 67, 3843–3859.
3. Jiang M#, Li WJ#, Liang JZ#, Pang M#, Li SH, Xu G, Zhu MH, Liang H, Zhang ZL*, Yang F*. Developing a palladium(II) agent to overcome multi-drug resistance and metastasis of liver tumor by targeted multi-acting on tumor cell, inactivating cancer-associated fibroblast and activating immune response. Journal of Medicinal Chemistry, 2024, 67, DOI:10.1021/acs.jmedchem.4c01175.
4. Li WJ, Li SH, Zhang ZL, Xu G, Man XY, Yang F*, Liang H*. Developing a multi-targeted anticancer palladium(II) agent based on the His-242 residue in IIA subdomain of human serum albumin. Journal of Medicinal Chemistry, 2023, 66, 8564–8579.
5. Li WJ, Li SH, Xu G, Man XY, Yang TF, Zhang ZL, Liang H*, Yang F*. Developing a ruthenium(III) complex to trigger gasdermin E-mediated pyroptosis and immune response based on decitabine and liposomes: targeting inhibition of gastric tumor growth and metastasis. Journal of Medicinal Chemistry, 2023, 66, 13072–13085.
6. Li WJ, Li SH, Man XY, Xu G, Zhang ZL, Zhang Yao, Liang H*, Yang F*. Designing a novel Au(III) agent to inhibit tumor growth and metastasis through immunogenic cell death induced by combination of endoplasmic reticulum stress and mitochondrial dysfunction. Rare Metals, 2024, https://doi.org/10.1007/s12598-024-02871-x.
学习经历：
2021/09-至今，广西师范大学化学与药学学院(博士在读)
2018/09-2021/06，广西师范大学化学与药学学院(硕士)，本课题组硕士
2014/09-2018/06，嘉应学院(学士)
邮箱：1286006878@qq.com